Intravitreal anti-vascular endothelial growth factor (anti-VEGF) with bevacizumab monotherapy, compared with conventional laser therapy in infants with stage 3 + retinopathy of prematurity, showed a significant benefit for zone I disease4. Here, VEGFA is linked to retinopathy of prematurity.